NRXP

NRX Pharmaceuticals Inc

2.19

Nov 02 • 11:03 AM ET -0.08 (-3.30%)

Healthcare Biotechnology USA Micro NASD

Oct 30, 7:05 AMNRx Pharmaceuticals gets FDA approval for Abbreviated New Drug Application for preservative-free ketamine injection ahead of Nov. 10 goal date

Peers: NMRA GHRS ANRO AXSM TNXP CMPS STIM LBRX VTGN SUPN

| Held by: VTI PSIL VXF IWC

Scroll to Statements

Index	-
Market Cap	95.03M
Enterprise Value	69.59M
Income	-23.48M
Sales	3.39M
Book/sh	-0.00
Cash/sh	0.62
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	29
IPO	Dec 04, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	28.03
P/B	-
P/C	3.56
P/FCF	-
EV/EBITDA	-
EV/Sales	20.53
Quick Ratio	0.86
Current Ratio	0.86
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.74
EPS next Y	-0.41
EPS next Q	-0.21
EPS this Y	35.12%
EPS next Y	52.91%
EPS next 5Y	-
EPS past 3/5Y	39.52% 38.42%
Sales past 3/5Y	- -
EPS Y/Y TTM	67.07%
Sales Y/Y TTM	-
EPS Q/Q	55.24%
Sales Q/Q	-
Earnings	Aug 17 BMO
EPS/Sales Surpr.	-312.37% -17.20%

Insider Own	11.62%
Insider Trans	0.00%
Inst Own	27.60%
Inst Trans	13.90%
ROA	-120.42%
ROE	-
ROIC	-8209.79%
Gross Margin	32.68%
Oper. Margin	-588.13%
Profit Margin	-691.81%
SMA20	-16.94%
SMA50	-27.62%
SMA200	-26.05%
Trades

Shs Outstand	43.16M
Shs Float	38.26M
Short Float	26.01%
Short Ratio	9.07
Short Interest	9.95M
52W High	5.05 -56.58%
52W Low	1.62 35.49%
Volatility	11.37% 7.46%
ATR (14)	0.21
RSI (14)	28.16
Beta	2.11
Rel Volume	3.40
Avg Volume	1.10M
Volume	1,032,102

Perf Week	-13.92%
Perf Month	-24.44%
Perf Quarter	-28.03%
Perf Half Y	-26.83%
Perf YTD	-19.00%
Perf Year	-29.19%
Perf 3Y	-28.80%
Perf 5Y	-97.68%
Perf 10Y	-
Recom	1.00
Target Price	38.50
Prev Close	2.27
Price	2.19
Change %	-3.30%

Consensus

Strong Buy

Avg. Price Target

$38.50

Implied Upside

+1,654.0%

Analysts2incl. previous ratings

Rating Distribution2 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 08, 2025	Initiated	HH.C. Wainwright	Buy	$40	+1,722.3%
Apr 02, 2025	Initiated	BBTIG Research	Buy	$18	+720.0%

Oct-30-26 07:00AM	NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date (GlobeNewswire) -14.66%
Oct-29-26 04:00PM	NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine (GlobeNewswire)
Oct-19-26 09:22AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
08:30AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine (GlobeNewswire)
Oct-15-26 08:27AM	NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine (GlobeNewswire)
07:00AM	Loading…
Sep-30-26 07:00AM	NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression (GlobeNewswire)
Sep-15-26 03:11PM	NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine (GlobeNewswire)
Sep-14-26 07:00AM	GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Sep-11-26 07:00AM	NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System (GlobeNewswire)
Sep-08-26 07:00AM	NRx Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-18-26 01:02AM	NRX Pharmaceuticals Inc (NRXP) (Q2 2026) Earnings Call Highlights: Advancing Ketamine Pipeline ... (GuruFocus.com)
Aug-17-26 03:26PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
07:00AM	NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET (GlobeNewswire)
Aug-07-26 04:01PM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans (GlobeNewswire) +15.86% -6.42%
07:00AM	FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval (GlobeNewswire)
04:01PM	Loading…
Jun-25-26 04:01PM	NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute (GlobeNewswire)
07:00AM	NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System (GlobeNewswire)
Jun-24-26 01:18PM	Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition (Business Wire) -5.32%
Jun-23-26 11:05AM	ZETA SURGICAL Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics (PR Newswire)
Jun-22-26 07:00AM	NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression (GlobeNewswire)
Jun-17-26 06:19PM	NRX Pharmaceuticals Inc (NRXP) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Jun-05-26 08:50AM	NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. (GlobeNewswire)
Jun-04-26 05:12PM	NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option (GlobeNewswire)
Jun-03-26 08:18AM	NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -12.34%
Jun-02-26 04:01PM	NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
May-28-26 07:00AM	NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026 (GlobeNewswire)
May-27-26 07:00AM	NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System (GlobeNewswire)
May-18-26 07:00AM	NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -5.03%
May-14-26 07:00AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update (GlobeNewswire) +8.81%
May-07-26 08:00AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality (GlobeNewswire)
07:00AM	Loading…
May-05-26 07:00AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine (GlobeNewswire)
Apr-22-26 07:00AM	NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program (GlobeNewswire)
Apr-20-26 07:00AM	NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality (GlobeNewswire) +25.49%
Apr-15-26 07:00AM	NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications (GlobeNewswire)
Apr-13-26 07:00AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer (GlobeNewswire)
Apr-06-26 09:08AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
07:00AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application (GlobeNewswire)
Mar-30-26 07:00AM	Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network (GlobeNewswire)
Mar-24-26 03:00PM	NRX Pharmaceuticals Inc (NRXP) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) +20.34%
07:00AM	NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress (GlobeNewswire)
Mar-19-26 07:00AM	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 (GlobeNewswire)
Mar-17-26 07:00AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application (GlobeNewswire) -6.25%
Mar-16-26 07:00AM	NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting (GlobeNewswire) +11.83%
Mar-11-26 04:59AM	Mutual Fund vs. ETF: Should You Buy VTSAX or VTI in 2026? (TipRanks)
Mar-09-26 07:00AM	HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD (GlobeNewswire)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks)
Mar-02-26 07:00AM	NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer (GlobeNewswire)
Feb-17-26 07:00AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting (GlobeNewswire)
Jan-27-26 04:02AM	New Strong Sell Stocks for January 27th (Zacks) +5.66%
Jan-16-26 07:03AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date (GlobeNewswire) +5.58%
Jan-14-26 07:03AM	NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval (GlobeNewswire)
Jan-05-26 06:57AM	NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions (GlobeNewswire) -8.02%
Dec-18-25 07:05AM	NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion (GlobeNewswire)
Dec-08-25 09:23AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-03-25 02:30PM	NRx Pharmaceuticals (NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment (NewMediaWire) +6.17%
07:00AM	NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation (GlobeNewswire)
Dec-02-25 02:30PM	NRx Pharmaceuticals (NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date (NewMediaWire) -5.02%
08:30AM	NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE, a Preservative-Free IV Ketamine (GlobeNewswire)
07:30AM	NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call (GlobeNewswire)
Dec-01-25 03:30PM	NRx Pharmaceuticals (NRXP) to Present at NobleCon21 (NewMediaWire)
08:03AM	NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference (GlobeNewswire)
Nov-17-25 04:01PM	NRX Pharmaceuticals Inc (NRXP) Q3 2025 Earnings Call Highlights: Strategic Clinic Expansion and ... (GuruFocus.com) -15.26% +8.06%
03:30PM	NRx Pharmaceuticals (NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs (NewMediaWire)
08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-13-25 03:42PM	NRx Pharmaceuticals (NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17 (NewMediaWire)
Nov-12-25 08:31AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025 (GlobeNewswire) +6.02%
Nov-10-25 03:15PM	NRx Pharmaceuticals (NRXP) Launches HOPE Therapeutics' One-Day TMS Protocol for Treatment-Resistant Depression in Florida (NewMediaWire)
08:03AM	HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health (GlobeNewswire)
Oct-27-25 02:30PM	NRx Pharmaceuticals (NRXP) Advancing Two-Pronged Approach to Bring Innovative Therapies to Market (NewMediaWire)
Oct-20-25 08:03AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director (GlobeNewswire)
Oct-17-25 03:00PM	NRx Pharmaceuticals (NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies (NewMediaWire)
Oct-09-25 02:36PM	NRx Pharmaceuticals (NRXP) Strengthens Pipeline With Dual Pathways for Ketamine-Based Therapies (NewMediaWire)
Oct-06-25 03:00PM	NRx Pharmaceuticals (NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference (NewMediaWire)
08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference (GlobeNewswire)
Sep-30-25 02:30PM	NRx Pharmaceuticals (NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM) (NewMediaWire)
Sep-29-25 08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE, Preservative-Free IV Ketamine (GlobeNewswire) +10.17%
Sep-24-25 03:00PM	NRx Pharmaceuticals (NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product (NewMediaWire)
08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine (GlobeNewswire)
Sep-09-25 03:00PM	NRx Pharmaceuticals (NRXP) Subsidiary HOPE Therapeutics Closes Acquisition of Dura Medical (NewMediaWire) +10.92%
Sep-08-25 08:17AM	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics (GlobeNewswire)
Sep-03-25 03:30PM	NRx Pharmaceuticals (NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression (NewMediaWire)
08:51AM	NRx Pharmaceuticals presents two keynote talks at 2025 Global Passion Project (TipRanks)
08:03AM	NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th (GlobeNewswire)
Sep-02-25 01:19PM	UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office (GlobeNewswire) +12.07%
08:41AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital (GlobeNewswire)
03:53AM	NRx Pharmaceuticals, Inc. (NRXP)' NRX-100 Wins Expanded FDA Fast Track for Suicidal Depression (Insider Monkey)
Aug-27-25 03:00PM	NRx Pharmaceuticals (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track Designation (NewMediaWire)
08:03AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine) (GlobeNewswire)
Aug-25-25 03:15PM	NRx Pharmaceuticals (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative (NewMediaWire)
Aug-21-25 03:05AM	NRX Pharmaceuticals Inc (NRXP) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
Aug-19-25 01:00PM	NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs (NewMediaWire) -9.24%
09:21AM	NRX Pharmaceuticals Inc (NRXP) Q2 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Aug-18-25 09:19AM	What To Expect From NRX Pharmaceuticals Inc (NRXP) Q2 2025 Earnings (GuruFocus.com)
08:10AM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-14-25 02:00PM	NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression (NewMediaWire) +5.53%
12:00PM	NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition (NewMediaWire)
Aug-13-25 06:06PM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025 (PR Newswire) +5.86%
02:00PM	NRx Pharmaceuticals (NASDAQ: NRXP) Petitions FDA to Ban Benzethonium Chloride From Ketamine Products (NewMediaWire)
Aug-12-25 03:47PM	NRx Pharmaceuticals (NASDAQ: NRXP) CEO to Join Fireside Chat at BTIG Virtual Biotechnology Conference (NewMediaWire)
Aug-11-25 04:05PM	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025 (GlobeNewswire) -7.94%

Show Previous News

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.

M.P.H.Dr. Jonathan C. Javitt M.D.

CFO & TreasurerMr. Michael S. Abrams M.B.A.

Chief Operating OfficerMr. Joseph M. Casper

Chief Manufacturing & Technology OfficerDr. Riccardo Panicucci Ph.D.

Ph.D.Dr. Herve Perron HDR

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRXP

NRX Pharmaceuticals Inc

Upgrade your Finviz experience